HCW Biologics Inc. (NASDAQ: HCWB) is now covered by analysts at Maxim Group. They set a "buy" rating and a $4.00 price target on the stock.
HCW Biologics Inc. (HCWB)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
HCWB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HCWB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HCWB alerts
High impacting HCW Biologics Inc. news events
Weekly update
A roundup of the hottest topics
HCWB
News
- HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid TumorsGlobeNewswire
- HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial Results [TheStreet.com]TheStreet.com
- HCW Biologics Reports Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights and Financial ResultsGlobeNewswire
- HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion Immunotherapeutic [Yahoo! Finance]Yahoo! Finance
- HCW Biologics Closes Exclusive Worldwide License for HCW11-006 – A High Potential Fusion ImmunotherapeuticGlobeNewswire
HCWB
Sec Filings
- 4/29/26 - Form DEF
- 4/28/26 - Form ARS
- 4/24/26 - Form S-1/A
- HCWB's page on the SEC website